Cover crops of oats, stooling rye and three annual ryegrass cultivars influence maize and Cyperus esculentus growth

No information is available on the effect of cover crops on weed growth in maize production in KwaZulu-Natal, South Africa. In a field experiment, the influence of two preceding cover crops, stooling rye and annual ryegrass, on the growth of maize and the weed Cyperus esculentus were compared with herbicides and weed control by hoeing. Maize emergence and early growth were delayed in the presence of physical residues of both cover crop species, especially in annual ryegrass residues. Growth of C. esculentus was significantly inhibited in the inter-row maize planting lines by the cover crops for the first 16 days after maize emergence, but this effect had diminished by day 28. In a pot experiment, the influence of the same two cover crops on maize and C. esculentus growth was evaluated together with oats and two additional annual ryegrass cultivars. Here the growth of maize and C. esculentus growth was suppressed, especially by the root residues of the annual ryegrass, in particular the cultivar Midmar. Chemical analysis of the leachate of the root residues indicated the presence of phenolic acids and benzoxazolin-2(3H)-one (BOA). In order to achieve effective weed control, a weed management strategy combining the mulch retained on the soil surface with a possible reduction in the type and amount of herbicide(s) should be implemented.http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-3180hb2017Plant Production and Soil Scienc

Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies

Aims We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. Methods The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses. Results 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied). Conclusions MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised